Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 3/20 | 0.31 |
| ▸ | PPARA | Q07869 | 3/20 | 0.31 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466231 | 0.91 | FAAH (0.35) | PPARGFAAHCES1DAGLAXDH | |
| SCHEMBL7044878 | 0.78 | ELANE (0.41) | ELANEFAAHCES1DAGLAXDH | |
| SCHEMBL6062665 | 0.74 | MTNR1A (0.35) | FAAHCES1DAGLAXDH | |
| SCHEMBL7049043 | 0.72 | MAPT (0.38) | ATM | |
| SCHEMBL7044871 | 0.71 | FAAH (0.40) | PPARGELANEFAAHCES1DAGLA | |
| SCHEMBL7049306 | 0.68 | DAGLA (0.44) | FAAHCES1DAGLAXDHNPC1 | |
| SCHEMBL7046959 | 0.67 | DAGLA (0.45) | PPARGELANEFAAHCES1DAGLA | |
| SCHEMBL6466202 | 0.67 | LMNA (0.36) | FAAHCES1DAGLAXDHNPC1 | |
| SCHEMBL6467037 | 0.67 | FAAH (0.36) | FAAHCES1DAGLAXDHNPC1 | |
| SCHEMBL6462741 | 0.67 | FAAH (0.36) | FAAHCES1DAGLAXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | PPARG 4143/4885ELANE 50/4885FAAH 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.